New drug targets Low-Oxygen cancers in early trial

NCT ID NCT04954599

Recruiting now Disease control Sponsor: Maastricht University Medical Center Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 29 times

Summary

This study tests a new drug called CP-506, which becomes active only in low-oxygen areas of solid tumors. It is given alone or with chemotherapy (carboplatin) or immunotherapy. The goal is to find safe doses and see if it helps control tumor growth. About 126 adults with advanced solid cancers will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Academisch Ziekenhuis Maastricht (Leading Centre)
RECRUITING

Maastricht, Limburg, 6229HX, Netherlands

Contact
Erasmus MC
RECRUITING

Rotterdam, Netherlands

Contact
Institut Jules Bordet
NOT_YET_RECRUITING

Brussels, Belgium

Contact
Institut Vall d'Hebron
NOT_YET_RECRUITING

Barcelona, 08035, Spain

Contact Phone: •••-•••-••••
UZ Gent
NOT_YET_RECRUITING

Ghent, 9000, Belgium

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC